Dual PI3K/mTOR Inhibitor NVP-BEZ235 Leads to a Synergistic Enhancement of Cisplatin and Radiation in Both HPV-Negative and -Positive HNSCC Cell Lines

SIMPLE SUMMARY: Head and neck cancers (HNSCCs), especially in the advanced stages, are predominantly treated by radiochemotherapy, including cisplatin. The cure rates are clearly higher for HPV-positive HNSCCs when compared to HPV-negative HNSCCs. For both entities, this treatment is accompanied by...

Descripción completa

Detalles Bibliográficos
Autores principales: Subtil, Florentine S. B., Gröbner, Carolin, Recknagel, Niklas, Parplys, Ann Christin, Kohl, Sibylla, Arenz, Andrea, Eberle, Fabian, Dikomey, Ekkehard, Engenhart-Cabillic, Rita, Schötz, Ulrike
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9265133/
https://www.ncbi.nlm.nih.gov/pubmed/35804930
http://dx.doi.org/10.3390/cancers14133160

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9265133/
https://www.ncbi.nlm.nih.gov/pubmed/35804930
http://dx.doi.org/10.3390/cancers14133160

Ejemplares similares